Compare BDSX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | VRCA |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.2M | 137.3M |
| IPO Year | 2020 | 2018 |
| Metric | BDSX | VRCA |
|---|---|---|
| Price | $14.59 | $6.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $32.50 | $17.00 |
| AVG Volume (30 Days) | 64.7K | ★ 83.6K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,499,000.00 | $35,577,000.00 |
| Revenue This Year | $25.26 | N/A |
| Revenue Next Year | $19.15 | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 24.08 | ★ 370.22 |
| 52 Week Low | $0.26 | $0.49 |
| 52 Week High | $20.21 | $9.82 |
| Indicator | BDSX | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 45.38 |
| Support Level | $13.46 | $5.13 |
| Resistance Level | $16.38 | $6.40 |
| Average True Range (ATR) | 1.00 | 0.68 |
| MACD | 0.08 | -0.17 |
| Stochastic Oscillator | 42.83 | 20.53 |
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.